• Explore /
  • Poster
  • / The prognostic value of tumor markers in patients (pts) with resectable gastric cancer (GC) receiving perioperative therapy in the CRITICS trial.

The prognostic value of tumor markers in patients (pts) with resectable gastric cancer (GC) receiving perioperative therapy in the CRITICS trial.

Abstract Video & Slides Poster

Authors

null

Astrid E. Slagter

Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, Netherlands

Astrid E. Slagter , Marieke A. Vollebergh , Irene A Caspers , Johanna W. van Sandick , Karolina Sikorska , Pehr A. Lind , Marianne Nordsmark , Hein Putter , Jeffrey P.B.M. Braak , Elma Meershoek – Klein Kranenbarg , Cornelis J.H. Van De Velde , Edwin PM Jansen , Annemieke Cats , Hanneke W.M. Van Laarhoven , Nicole C.T. van Grieken , Marcel Verheij

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4024)

DOI

10.1200/JCO.2021.39.15_suppl.4024

Abstract #

4024

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2018 Gastrointestinal Cancers Symposium

BEACON CRC study safety lead-in (SLI) in patients with <em>BRAF</em><sup>V600E</sup> metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer (mCRC): Efficacy and tumor markers.

First Author: Eric Van Cutsem

First Author: Marlies Michl

First Author: J. Jo

First Author: Li-Yue Sun